Kilpatrick Townsend’s Silicon Valley-based start-up team advised the founders of Editas Medicine in the biotech start-up’s $43 million Series A Financing. In a trend setting transaction, venture firms Polaris Partners, Third Rock Ventures, Flagship Ventures and the Partners Innovation Fund invited five of the most prominent research scientists in the field of genomics from MIT, Harvard, the Howard Hughes Medical Institute and the University of California in Berkeley to form a company which they would fund. The money invested will fund the collaborative research and development by this world-class team of scientists as they seek to revolutionize the treatment of genetic disorders by developing a simple, precise and inexpensive method of ‘editing out’ abnormalities in genes in human cells.

Experience Center

Match our Experience to Your Needs

View All Case Studies

Experience Highlights

Union organizing campaign strategy for one of the largest U.S. forest products manufacturers
Advised one of the largest U.S. forest products manufacturers regarding strategy in a union organizing campaign in Bowling Green, Kentucky by the more
Brownfields Agreement for property redevelopment for clothing manufacturer
Represented manufacturer as the developer in negotiations with the NC Department of Environment and Natural Resources to obtain a Brownfields more
Multiple acquisitions by New York Community Bancorp Inc.
Represented New York Community Bancorp Inc. in its $168.4 million acquisition of Synergy Financial Group Inc., its $260.0 million acquisition of more
China expansion for one of the world's leading providers of lighting fixtures
Represented one of the world's leading providers of lighting fixtures and related products and services in structuring its expanding operations in more